Factors predicting the occurrence of net adverse clinical and cerebral events in patients with acute coronary syndrome treated with clopidogrel or ticagrelor in combination with aspirin: a real-world study.

ABSTRACT:

Background

This study aimed to establish the factors influencing the clinical benefits of ticagrelor and clopidogrel for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) surgery.

Methods

A multicenter, retrospective, real-world study was conducted on patients with ACS whose data were sourced from 3 databases, namely the BRIC-ACS(I) study, COSTIC study, and 301 Hospital PCI patient database from January 2014 to October 2017. The primary endpoint was net adverse clinical and cerebral events (NACCE).

Results

A total of 7,236 ACS patients were included, of which 4,444 patients (61.4%) and 2,792 patients (38.6%) were in the clopidogrel dual antiplatelet therapy (DAPT) group and ticagrelor DAPT group, respectively. The hazard ratio

SUBMITTER: Huang M 

PROVIDER: S-EPMC8848390 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature